Pregabalin in Treating Women With Hot Flashes

Alliance for Clinical Trials in Oncology

Status and phase: Completed; Phase 3

Conditions: Breast Cancer; Hot Flashes

Treatments: Other: placebo; Drug: pregabalin

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00702949

NCCTG-N07C1

CDR0000598191 (Registry Identifier)

NCI-2012-02716 (Registry Identifier)

Details and patient eligibility

About

RATIONALE: Pregabalin may help relieve hot flashes in women with a history of breast cancer or those who have no history and do not wish to take estrogen therapy for fear of increased risk of breast cancer. It is not yet known what dose of pregabalin may be more effective in treating hot flashes.

PURPOSE: This is a randomized phase III trial to determine the efficacy of two doses of pregabalin, in comparison to placebo, in the prevention of hot flashes.

Full description

OBJECTIVES:

• To evaluate the efficacy of 150 mg of pregabalin versus placebo on hot flash scores in women with a history of breast cancer or women who do not wish to take estrogen therapy for fear of increased risk of breast cancer.
• To evaluate the side effect profile of different doses of pregabalin in these patients.
• To evaluate the effect of 150 mg of pregabalin versus placebo on the secondary outcome of interference of activities from hot flashes in these patients.
• To evaluate the efficacy and side effect profile of 75 mg of pregabalin versus placebo in these patients.

OUTLINE: Patients are stratified according to age (18-49 years vs ≥ 50 years); selective estrogen-receptor modulator (i.e., tamoxifen or raloxifene) or aromatase inhibitor use (yes vs no); duration of hot flashes (< 9 months vs ≥ 9 months); and frequency of hot flashes per 24-hour period (4-9 vs ≥ 10). Patients are randomized to 1 of 3 treatment arms.

• Arm I: Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.
• Arm II: Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.
• Arm III: Patients receive oral placebo twice daily for 6 weeks. Treatment in all arms continues in the absence of unacceptable toxicity.

Patients complete Hot Flash Diaries at baseline and once daily during treatment and the Symptom Experience Diary at baseline and once weekly during treatment. Patients also complete the Profile of Mood States and the Hot Flash Related Daily Interference Scale questionnaires at baseline and after completion of study treatment.

Enrollment: 207 patients

Sex: Female

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Meeting 1 of the following criteria:

  • History of breast cancer (currently without malignant disease)
  • No history of breast cancer, but patient wishes to avoid estrogen due to a perceived increased risk of breast cancer

• Bothersome hot flashes (defined by their occurrence ≥ 28 times per week and of sufficient severity to make the patient desire therapeutic intervention)

• Presence of hot flashes for ≥ 1 month prior to study entry

PATIENT CHARACTERISTICS:

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Life expectancy ≥ 6 months
• Able to complete questionnaire(s) by themselves or with assistance
• Women of childbearing potential not eligible (per the judgment of the attending clinician)
• Serum creatinine ≤ 1.5 times upper limit of normal

PRIOR CONCURRENT THERAPY:

• No prior gabapentin or pregabalin

• More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, or progestational agents

  • Vaginal estrogen is allowed if used for the past month and not planned to be discontinued

• Concurrent adjuvant targeted therapy (i.e., lapatinib, trastuzumab [Herceptin®]) allowed in patients with no evidence of disease

• Concurrent tamoxifen, raloxifene, or aromatase inhibitors on a constant dose for at least 4 weeks allowed provided the medication will not be stopped during the study period

• No concurrent or planned use of other agents for hot flashes except for any of the following:

  • Stable dose of vitamin E is allowed as long as agent was started > 30 days prior to study initiation and is to be continued throughout the study period
  • Soy is allowed, if it is planned to be continued at the same dose during the study period
  • Stable dose of antidepressants is allowed as long as it was started > 30 days prior to study initiation and is to be continued at a stable dose throughout the study period

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

207 participants in 3 patient groups, including a placebo group

Pregabalin75

Experimental group

Description:

Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.

Treatment:

Drug: pregabalin

Pregabalin150

Experimental group

Description:

Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.

Treatment:

Drug: pregabalin

Placebo

Placebo Comparator group

Description:

Patients receive oral placebo twice daily for 6 weeks.

Treatment:

Other: placebo